Related references
Note: Only part of the references are listed.Technical Aspects of Flow Cytometry-based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party
Jesse M. Tettero et al.
HEMASPHERE (2022)
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
Michael Heuser et al.
BLOOD (2021)
Clinical impact of panel-based error-corrected next generation sequencing versus flow cytometry to detect measurable residual disease (MRD) in acute myeloid leukemia (AML)
Nikhil Patkar et al.
LEUKEMIA (2021)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Bob Lowenberg et al.
BLOOD ADVANCES (2021)
How I investigate acute myeloid leukemia
Damodaran Narayanan et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2020)
Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment
Guan-hua Hu et al.
BMC CANCER (2020)
Association of Measurable Residual Disease With Survival Outcomes in Patients With Acute Myeloid Leukemia A Systematic Review and Meta-analysis
Nicholas J. Short et al.
JAMA ONCOLOGY (2020)
Genomic landscape in acute myeloid leukemia and its implications in risk classification and targeted therapies
Hsin-An Hou et al.
JOURNAL OF BIOMEDICAL SCIENCE (2020)
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia
Adriano Venditti et al.
BLOOD (2019)
CD34+CD38- leukemic stem cell frequency to predict outcome in acute myeloid leukemia
Wendelien Zeijlemaker et al.
LEUKEMIA (2019)
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
Gerrit J. Schuurhuis et al.
BLOOD (2018)
Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia
Kiyomi Morita et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Minimal Residual Disease in Acute Myeloid Leukemia
M. Jongen-Lavrencic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
Hartmut Doehner et al.
BLOOD (2017)
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes
Eline M. P. Cremers et al.
HAEMATOLOGICA (2017)
Implementation of erythroid lineage analysis by flow cytometry in diagnostic models for myelodysplastic syndromes
Eline M. P. Cremers et al.
HAEMATOLOGICA (2017)
Best practices in performing flow cytometry in a regulated environment: feedback from experience within the European Bioanalysis Forum
Barry van der Strate et al.
BIOANALYSIS (2017)
The Prognostic Significance of Measurable (Minimal) Residual Disease in Acute Myeloid Leukemia
Francesco Buccisano et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Harmonemia: a universal strategy for flow cytometry immunophenotyping-A European LeukemiaNet WP10 study
F. Lacombe et al.
LEUKEMIA (2016)
Marked Variability in Reported Minimal Residual Disease Lower Level of Detection of 4 Hematolymphoid Neoplasms A Survey of Participants in the College of American Pathologists Flow Cytometry Proficiency Testing Program
Michael Keeney et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2015)
The evolution of guidelines for the validation of flow cytometric methods
L. Du et al.
INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY (2015)
Acute Myeloid Leukemia
Hartmut Doehner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
MRD in AML: It is time to change the definition of remission
Gert J. Ossenkoppele et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2014)
Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for prime time?
David Grimwade et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Validation of Cell-based Fluorescence Assays: Practice Guidelines from the ICSH and ICCS - Part V - Assay Performance Criteria
Brent Wood et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2013)
High Prognostic Impact of Flow Cytometric Minimal Residual Disease Detection in Acute Myeloid Leukemia: Data From the HOVON/SAKK AML 42A Study
Monique Terwijn et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
EuroFlow standardization of flow cytometer instrument settings and immunophenotyping protocols
T. Kalina et al.
LEUKEMIA (2012)
Review of the relevance of aberrant antigen expression by flow cytometry in myeloid neoplasms
Gert J. Ossenkoppele et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Rare-event analysis in flow cytometry
Albert D. Donnenberg et al.
CLINICS IN LABORATORY MEDICINE (2007)
Share Paper
